Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate Biomarkers for Alzheimer's Disease

Gajanan Sathe, Chan Hyun Na, Santosh Renuse, Anil K. Madugundu, Marilyn Albert, Abhay Moghekar, Akhilesh Pandey

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: The aim of this study is to identify the potential cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease and to evaluate these markers on independent CSF samples using parallel reaction monitoring (PRM) assays. Experimental Design: High-Resolution mass spectrometry and tandem mass tag (TMT) multiplexing technology are employed to identify potential biomarkers for Alzheimer's disease. Some of the identified potential biomarkers are validated using PRM assays. Results: A total of 2327 proteins are identified in the CSF of which 139 are observed to be significantly altered in the CSF of AD patients. The proteins altered in AD includes a number of known AD marker such as MAPT, NPTX2, VGF, GFAP, and NCAM1 as well as novel biomarkers such as PKM and YWHAG. These findings are validated in a separate set of CSF specimens from AD dementia patients and controls. NPTX2, in combination with PKM or YWHAG, leads to the best results with AUCs of 0.935 and 0.933, respectively. Conclusions and Clinical Relevance: The proteins that are found to be altered in the CSF of patients with AD could be used for monitoring disease progression and therapeutic response and perhaps also for early detection once they are validated in larger studies.

Original languageEnglish (US)
Article number1800105
JournalProteomics - Clinical Applications
Volume13
Issue number4
DOIs
StatePublished - Jul 1 2019
Externally publishedYes

Fingerprint

Cerebrospinal fluid
Biomarkers
Proteomics
Cerebrospinal Fluid
Alzheimer Disease
Tandem Mass Spectrometry
Monitoring
Assays
Proteins
Multiplexing
Design of experiments
Area Under Curve
Mass spectrometry
Dementia
Disease Progression
Research Design
Technology

Keywords

  • Alzheimer's disease
  • biomarker
  • biomedical applications
  • cerebrospinal fluid
  • mass spectrometry
  • parallel reaction monitoring
  • proteome
  • TMT

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate Biomarkers for Alzheimer's Disease. / Sathe, Gajanan; Na, Chan Hyun; Renuse, Santosh; Madugundu, Anil K.; Albert, Marilyn; Moghekar, Abhay; Pandey, Akhilesh.

In: Proteomics - Clinical Applications, Vol. 13, No. 4, 1800105, 01.07.2019.

Research output: Contribution to journalArticle

Sathe, Gajanan ; Na, Chan Hyun ; Renuse, Santosh ; Madugundu, Anil K. ; Albert, Marilyn ; Moghekar, Abhay ; Pandey, Akhilesh. / Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate Biomarkers for Alzheimer's Disease. In: Proteomics - Clinical Applications. 2019 ; Vol. 13, No. 4.
@article{868e20010fd543b9ba333c67d46d8310,
title = "Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate Biomarkers for Alzheimer's Disease",
abstract = "Purpose: The aim of this study is to identify the potential cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease and to evaluate these markers on independent CSF samples using parallel reaction monitoring (PRM) assays. Experimental Design: High-Resolution mass spectrometry and tandem mass tag (TMT) multiplexing technology are employed to identify potential biomarkers for Alzheimer's disease. Some of the identified potential biomarkers are validated using PRM assays. Results: A total of 2327 proteins are identified in the CSF of which 139 are observed to be significantly altered in the CSF of AD patients. The proteins altered in AD includes a number of known AD marker such as MAPT, NPTX2, VGF, GFAP, and NCAM1 as well as novel biomarkers such as PKM and YWHAG. These findings are validated in a separate set of CSF specimens from AD dementia patients and controls. NPTX2, in combination with PKM or YWHAG, leads to the best results with AUCs of 0.935 and 0.933, respectively. Conclusions and Clinical Relevance: The proteins that are found to be altered in the CSF of patients with AD could be used for monitoring disease progression and therapeutic response and perhaps also for early detection once they are validated in larger studies.",
keywords = "Alzheimer's disease, biomarker, biomedical applications, cerebrospinal fluid, mass spectrometry, parallel reaction monitoring, proteome, TMT",
author = "Gajanan Sathe and Na, {Chan Hyun} and Santosh Renuse and Madugundu, {Anil K.} and Marilyn Albert and Abhay Moghekar and Akhilesh Pandey",
year = "2019",
month = "7",
day = "1",
doi = "10.1002/prca.201800105",
language = "English (US)",
volume = "13",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag",
number = "4",

}

TY - JOUR

T1 - Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate Biomarkers for Alzheimer's Disease

AU - Sathe, Gajanan

AU - Na, Chan Hyun

AU - Renuse, Santosh

AU - Madugundu, Anil K.

AU - Albert, Marilyn

AU - Moghekar, Abhay

AU - Pandey, Akhilesh

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Purpose: The aim of this study is to identify the potential cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease and to evaluate these markers on independent CSF samples using parallel reaction monitoring (PRM) assays. Experimental Design: High-Resolution mass spectrometry and tandem mass tag (TMT) multiplexing technology are employed to identify potential biomarkers for Alzheimer's disease. Some of the identified potential biomarkers are validated using PRM assays. Results: A total of 2327 proteins are identified in the CSF of which 139 are observed to be significantly altered in the CSF of AD patients. The proteins altered in AD includes a number of known AD marker such as MAPT, NPTX2, VGF, GFAP, and NCAM1 as well as novel biomarkers such as PKM and YWHAG. These findings are validated in a separate set of CSF specimens from AD dementia patients and controls. NPTX2, in combination with PKM or YWHAG, leads to the best results with AUCs of 0.935 and 0.933, respectively. Conclusions and Clinical Relevance: The proteins that are found to be altered in the CSF of patients with AD could be used for monitoring disease progression and therapeutic response and perhaps also for early detection once they are validated in larger studies.

AB - Purpose: The aim of this study is to identify the potential cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease and to evaluate these markers on independent CSF samples using parallel reaction monitoring (PRM) assays. Experimental Design: High-Resolution mass spectrometry and tandem mass tag (TMT) multiplexing technology are employed to identify potential biomarkers for Alzheimer's disease. Some of the identified potential biomarkers are validated using PRM assays. Results: A total of 2327 proteins are identified in the CSF of which 139 are observed to be significantly altered in the CSF of AD patients. The proteins altered in AD includes a number of known AD marker such as MAPT, NPTX2, VGF, GFAP, and NCAM1 as well as novel biomarkers such as PKM and YWHAG. These findings are validated in a separate set of CSF specimens from AD dementia patients and controls. NPTX2, in combination with PKM or YWHAG, leads to the best results with AUCs of 0.935 and 0.933, respectively. Conclusions and Clinical Relevance: The proteins that are found to be altered in the CSF of patients with AD could be used for monitoring disease progression and therapeutic response and perhaps also for early detection once they are validated in larger studies.

KW - Alzheimer's disease

KW - biomarker

KW - biomedical applications

KW - cerebrospinal fluid

KW - mass spectrometry

KW - parallel reaction monitoring

KW - proteome

KW - TMT

UR - http://www.scopus.com/inward/record.url?scp=85060622604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060622604&partnerID=8YFLogxK

U2 - 10.1002/prca.201800105

DO - 10.1002/prca.201800105

M3 - Article

VL - 13

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

IS - 4

M1 - 1800105

ER -